NCT06346808View on ClinicalTrials.gov

Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2026

Study Completion Date

May 1, 2027

Conditions
Pancreatic Cancer
Interventions
DRUG

Oncolytic virus Plus Anti-PD1 and Chemotherapy

Oncolytic virus，Camrelizumab ，AG（Gemcitabine +Capecitabine ）

Trial Locations (1)

610000

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan University

OTHER

NCT06346808 - Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC | Biotech Hunter | Biotech Hunter